Trial Profile
A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ceralasertib in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Ceralasertib (Primary) ; Carboplatin; Durvalumab; Olaparib
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Lung cancer; Male breast cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AstraZeneca
- 21 Nov 2023 Planned End Date changed from 18 Jun 2026 to 5 Aug 2026.
- 21 Nov 2023 Planned primary completion date changed from 18 Jun 2026 to 5 Aug 2026.
- 24 Oct 2023 Trial design, presented at the 48th European Society for Medical Oncology Congress